The eIF4E/4E-BP1 ratio is a key determinant of cell response to mTOR inhibitors as tumour cells with a high eIF4E/4E-BP1 ratio exhibit low sensitivity to asTORi-induced cell proliferation arrest [23, 24, 37]. The gene discussed is EIF4EBP1; the disease is neoplasm.